Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

今日，第一三共（Daiichi Sankyo）与阿斯利康（AstraZeneca）共同宣布，其联合开发的重磅抗体偶联药物（ADC）Enhertu（trastuzumab deruxtecan）获美国FDA批准，用于治疗不可切除或转移性激素受体（HR）阳性、HER2低表达（IHC 1+或IHC 2+/ISH-）或HER2超低（带有膜染色的IHC 0 ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

2024财年，Enhertu在HER2阳性乳腺癌二线治疗和HER2低表达乳腺癌适应症上，都实现了两位数的增长。在美国、欧洲和日本，Enhertu在各适应症的新患者 ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.